Sponsoring Agency HHS
    POP 1/25/10 - 7/31/15 (5 years)


The National Cancer Institute (NCI) is expanding its basic and translational research programs that rely heavily on sufficient availability of high quality well annotated biospecimens suitable for use in genomic studies. The NCI's overarching goal with such programs is to improve the ability to diagnose, treat, and prevent cancer. The Cancer Genome Atlas (TCGA), one such program, is a comprehensive and coordinated effort to accelerate our understanding of the molecular basis of cancer through the application of genome analysis technologies. As such, the NCI has awarded a Master IDIQ for clinically annotated biospecimens to TCGA for the following cancer types: Glioblastoma multiforme, Lung squamous cell carcinoma, Breast ductal carcinoma, Colon adenocarcinoma, Breast lobular carcinoma, Lung Adenocarcinoma , Stomach adenocarcinoma, and Other Cancer Types.

  • $12.4m Aggregate Dollars Obligated
  • $12.4m Aggregate Base & Exercised Options
  • $12.4m Aggregate Base & All Options (Ceiling)

Market Stats Related Contracts